Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Chronic Urticaria

Chronic Urticaria

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Chronic Urticaria

10 trials tracked for Chronic Urticaria: 6 in phase 3 or 4 and 3 with published results. The most-cited published study has 36 citations.

10Trials tracked
6Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 3 Phase 3 3 Phase 2 2 Other / NA 2
  1. Phase 4 Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU) Completed · 36 cited
  2. Phase 4 Safety Study of Levocetirizine and Fexofenadine Completed · 20 cited
  3. Phase 4 Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria Completed · 4 cited
  4. Phase 3 Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria Completed
  5. Phase 3 Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin Completed
  6. Phase 3 Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months Completed
Show 4 more trials
  1. Phase 2 Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria Completed
  2. Phase 2 A Study to Assess the Efficacy and Safety of AK002 in Subjects With Antihistamine-Resistant Chronic Urticaria Completed
  3. N/A Natural History of Chronic Urticaria Completed
  4. N/A The Validity, Reliability and Interpretability of Thai-version of Chronic Urticaria Quality of Life Questionnaire Completed

Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Chronic Urticaria: what the trials found

Omalizumab has been shown to impact clinical symptoms in chronic urticaria, specifically regarding the time to a 50% decline in the Urticaria Activity Score Seven Day (UAS7) [1, 3].

The intervention TEV-45779 demonstrated significant reductions in both the ISS7 and UAS7 scores at weeks 4 and 12. Specifically, mean changes from baseline for the ISS7 were -7.64, -7.35, -7.87, -7.27, -10.92, and -9.96 4. At week 12, the average reduction in UAS7 scores was approximately -21 to -22 points across study arms, with nearly half of the participants achieving a UAS7 score of ≤6 by week 12 4.

Levocetirizine has been evaluated in multiple trials for the management of chronic urticaria [2, 5, 6]. Clinical assessments using the Visual Analogue Scale (VAS) for pruritus showed scores of 11.5, 25.4, and 46.0 under this intervention 2.

Recent results — preliminary, needs further review

  • AK002 showed changes in Urticaria Control Test (UCT) scores from baseline to week 22 ranging from 3.4 to 11.1 7.
  • Omalizumab (75-375 mg) was associated with a reduction in UAS7 scores of -5.8 to -17.8 and changes in Skindex scores between -0.9 and 1.8 by week 24 8.
  • The Thai-version CU-Q2oL demonstrated cross-cultural validity (p<0.01) and reliability (p<0.05) for assessing quality of life 9.

For the clinician treating this condition

  • TEV-45779 significantly reduces both ISS7 and UAS7 scores, with approximately 46-50% of patients achieving a UAS7 score ≤6 at week 12.
  • Omalizumab is established as an intervention that can reduce the time to significant clinical symptom improvement (UAS7).
  • Levocetirizine is a documented treatment for managing symptoms including pruritus.

AI synthesis of 5 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this condition. Check back soon.